Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.

British journal of haematology - 1 Jun 2014

Ogura Michinori, Ando Kiyoshi, Suzuki Tatsuya, Ishizawa Kenichi, Oh Sung Yong, Itoh Kuniaki, Yamamoto Kazuhito, Au Wing Yan, Tien Hwei-Fang, Matsuno Yoshihiro, Terauchi Takashi, Yamamoto Keiko, Mori Masahiko, Tanaka Yoshinobu, Shimamoto Takashi, Tobinai Kensei, Kim Won Seog

Abstract excerpt

Although initial rituximab-containing chemotherapies achieve high response rates, indolent B-cell non-Hodgkin lymphoma (B-NHL), such as follicular lymphoma (FL), is still incurable. Therefore, new effective agents with novel mechanisms are anticipated. In this multicentre phase II study, patients with relapsed/refractory indolent B-NHL and mantle cell lymphoma (MCL) received vorinostat 200 mg twice daily for 14...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Combined Modality Therapy
Share to CREB-Binding Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to E1A-Associated p300 Protein

Share to Hydroxamic Acids

Share to Lymphoma, B-Cell

Share to Lymphoma, Mantle-Cell

Share to Neoplasm Grading

Share to Vorinostat

Source

Open in PubMed Open full text

Identifiers

PMID: 24617454
DOI: 10.1111/bjh.12819
PMCID: PMC4282031

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.PMID 24617454Read ↗

Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial.Semantic proximity Read ↗

Tazemetostat for relapsed/refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan: 3-year follow-up for a phase II study.Semantic proximity Read ↗

Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma.Semantic proximity Read ↗

Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas.Semantic proximity Read ↗

Rituximab resistance.Semantic proximity Read ↗

Matched unrelated donor stem cell transplant in 131 patients with follicular lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow TransplantationSemantic proximity Read ↗

Phase II study of tazemetostat for relapsed or refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan.Semantic proximity Read ↗

Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.Semantic proximity Read ↗

Rituximab is effective for human herpesvirus-8-negative primary effusion lymphoma with CD20 phenotype associated hepatitis C virus-related liver cirrhosis.Semantic proximity Read ↗

Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma.Semantic proximity Read ↗

Phase 1/2 study of ocaratuzumab, an Fc-engineered humanized anti-CD20 monoclonal antibody, in low-affinity FcγRIIIa patients with previously treated follicular lymphoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.